Canaccord Genuity analyst Randall Stanicky lines up three specialty pharmaceutical stocks with strong catalyst-driven upside potential before year-end: (1) Teva Pharmaceuticals (TEVA -0.3%) on generic Lipitor potential; (2) Inhibitex (INHX -0.1%) ahead of top-line results from INX-189; (3) Raptor (RPTP +0.3%) due to key six-month tolerability data set to be released in Dec.
Canaccord Genuity analyst Randall Stanicky lines up three specialty pharmaceutical stocks with...
From other sites
Video at CNBC.com (Jul 13, 2016)
Video at CNBC.com (Jun 26, 2016)
Video at CNBC.com (May 9, 2016)
Video at CNBC.com (Mar 28, 2016)
at CNBC.com (Jan 5, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs